Overcoming tamoxifen resistance in oestrogen receptor‐positive breast cancer using the novel thiosemicarbazone anti‐cancer agent, DpC

THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Catalytic receptors

(2019) Stephen P H Alexander et al.   BRITISH JOURNAL OF PHARMACOLOGY

THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Nuclear hormone receptors

(2019) Stephen P H Alexander et al.   BRITISH JOURNAL OF PHARMACOLOGY

THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Enzymes

(2019) Stephen P H Alexander et al.   BRITISH JOURNAL OF PHARMACOLOGY

MTA1 is a novel regulator of autophagy that induces tamoxifen resistance in breast cancer cells

(2018) Min-Ho Lee et al.   Autophagy

Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers

(2018) Michael J Curtis et al.   BRITISH JOURNAL OF PHARMACOLOGY

Therapeutically targeting tumor microenvironment–mediated drug resistance in estrogen receptor–positive breast cancer

(2018) Kevin Shee et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Novel Thiosemicarbazones Inhibit Lysine-Rich Carcinoembryonic Antigen–Related Cell Adhesion Molecule 1 (CEACAM1) Coisolated (LYRIC) and the LYRIC-Induced Epithelial-Mesenchymal Transition via Upregulation of N-Myc Downstream-Regulated Gene 1 (NDRG1)

(2017) Ruxing Xi et al.   MOLECULAR PHARMACOLOGY

The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY

(2017) Simon D Harding et al.   NUCLEIC ACIDS RESEARCH

MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours

(2016) Andrew R Green et al.   BRITISH JOURNAL OF CANCER

The novel thiosemicarbazone, di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), inhibits neuroblastoma growth in vitro and in vivo via multiple mechanisms

(2016) Zhu-Ling Guo et al.   Journal of Hematology & Oncology

The Metastasis Suppressor, N-MYC Downstream-regulated Gene-1 (NDRG1), Down-regulates the ErbB Family of Receptors to Inhibit Downstream Oncogenic Signaling Pathways

(2015) Zaklina Kovacevic et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The renaissance of polypharmacology in the development of anti-cancer therapeutics: Inhibition of the “Triad of Death” in cancer by Di-2-pyridylketone thiosemicarbazones

(2015) Patric J. Jansson et al.   PHARMACOLOGICAL RESEARCH

Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents

(2015) Vit Sestak et al.   Oncotarget

Targeting cancer by binding iron: Dissecting cellular signaling pathways

(2015) Goldie Y.L. Lui et al.   Oncotarget

Three-Dimensional Cell Culture Systems and Their Applications in Drug Discovery and Cell-Based Biosensors

(2014) Rasheena Edmondson et al.   ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES

N-myc Downstream Regulated 1 (NDRG1) Is Regulated by Eukaryotic Initiation Factor 3a (eIF3a) during Cellular Stress Caused by Iron Depletion

(2013) Darius J. R. Lane et al.   PLoS One

Tamoxifen Resistance in Breast Cancer

(2012) Min-Sun Chang   Biomolecules & Therapeutics

Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit

(2012) Josefine Bostner et al.   BREAST CANCER RESEARCH AND TREATMENT

The Iron Chelators Dp44mT and DFO Inhibit TGF-β-induced Epithelial-Mesenchymal Transition via Up-Regulation of N-Myc Downstream-regulated Gene 1 (NDRG1)

(2012) Zhiqiang Chen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Novel Second-Generation Di-2-Pyridylketone Thiosemicarbazones Show Synergism with Standard Chemotherapeutics and Demonstrate Potent Activity against Lung Cancer Xenografts after Oral and Intravenous Administration in Vivo

(2012) David B. Lovejoy et al.   JOURNAL OF MEDICINAL CHEMISTRY

Novel Thiosemicarbazone Iron Chelators Induce Up-Regulation and Phosphorylation of the Metastasis Suppressor N-myc Down-Stream Regulated Gene 1: A New Strategy for the Treatment of Pancreatic Cancer

(2011) Z. Kovacevic et al.   MOLECULAR PHARMACOLOGY

Update on the molecular profile of the MDA-MB-453 cell line as a model for apocrine breast carcinoma studies

(2011) SEMIR VRANIC et al.   Oncology Letters

3D tumour models: novel in vitro approaches to cancer studies

(2011) Agata Nyga et al.   Journal of Cell Communication and Signaling

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

Ki67 in breast cancer: prognostic and predictive potential

(2010) Rinat Yerushalmi et al.   LANCET ONCOLOGY

Expression of Estrogen Receptor Beta and Phosphorylation of Estrogen Receptor Alpha Serine 167 Correlate with Progression-Free Survival in Patients with Metastatic Breast Cancer Treated with Aromatase Inhibitors

(2010) Kazuyoshi Motomura et al.   ONCOLOGY

Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways

(2009) Sandra E. Ghayad et al.   INTERNATIONAL JOURNAL OF CANCER

NF-κB and estrogen receptor α interactions: Differential function in estrogen receptor-negative and -positive hormone-independent breast cancer cells

(2009) Nathalie Gionet et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Estrogen signals via an extra-nuclear pathway involving IGF-1R and EGFR in tamoxifen-sensitive and -resistant breast cancer cells

(2008) Richard J. Santen et al.   STEROIDS